Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids
August 09 2022 - 8:00AM
Ceapro Inc. (TSX-V: CZO;
OTCQX: CRPOF) (“Ceapro” or the
“Company”), a growth-stage biotechnology company focused
on the development and commercialization of active ingredients for
healthcare and cosmetic industries, announced today that positive
results from a collaborative project with University of Alberta
researchers have been accepted for publication in The Journal of
Supercritical Fluids in an article titled, “Supercritical
adsorptive precipitation of coenzyme Q10 on sodium alginate
aerogel,” authored by Zixiang Liu, Ricardo Couto, Bernhard
Seifried, Byron Yépez, Paul Moquin and Feral Temelli.
The data reported in this peer-reviewed
publication originated from the extensive three-year collaborative
project completed in April 2021 under the leadership of Dr. Feral
Temelli at University of Alberta. While this screening program
generated a wealth of data and insight with many PGX-processed
biopolymers, Sodium Alginate (SA), an extract from brown algae, was
retained as the most promising candidate to be included in Ceapro’s
pipeline. Results from the work investigating the effect of PGX
processing parameters and scale-up on the physicochemical
properties of PGX-SA as a stand alone novel bioaerogel were
published in May 2022 however, results in this article demonstrate
that PGX-SA can be homogeneously and more easily loaded with even
higher amount of coenzyme Q10 (CoQ10) than other previously
PGX-processed biopolymers using supercritical adsorptive
precipitation.
Investigators also determined that the CoQ10 is
finely deposited onto the PGX-SA in an amorphous form and forms a
stable dispersion in water. Given that the amorphous form of CoQ10
is considered to be more bioavailable, it was concluded that PGX-SA
could be used to generate more potent CoQ10 supplements. This is an
important finding since CoQ10 plays an essential role in
maintaining cellular functions and energy generation in humans and,
according to some reports, adequate supplementation is recommended
after the age of 40. So far, adequate CoQ10 supplementation has
been challenging due to the hydrophobic nature of CoQ10 and the
reported low bioavailability of most commercial CoQ10 supplements.
Results demonstrated in this in vitro study, along with upcoming
expected results from an ongoing animal bioavailability study being
conducted at University of Alberta, will determine if Ceapro can
solve this challenge.
“We are very pleased with these results as it
will enable Ceapro to expand its pipeline and develop PGX-processed
alginate as a stand alone and/or in combination with CoQ10 or other
bioactives to form new chemical complexes that can act as delivery
systems under different forms of administration. While
PGX-processed alginate is poised to become a key commercial
strategic asset for the Company along with beta glucan from yeast,
findings of this study could lead to the development of many other
more potent delivery systems enabling Ceapro to expand into a
high-end Life Science company,” said Gilles Gagnon, M.Sc., MBA,
President and CEO.
About Pressurized Gas eXpanded Liquid Technology
(PGX)
Ceapro’s patented Pressurized Gas eXpanded (PGX)
technology is a unique and disruptive technology with several key
advantages over conventional drying and purification technologies
that can be used to process biopolymers into high-value,
fine-structured, openporous polymer structures and novel
biocomposites. PGX is ideally suited for processing challenging
high-molecular-weight, water-soluble biopolymers. It has the
ability to make ultra-light, highly porous polymer structures on a
continuous basis, which is not possible using today's conventional
technologies. PGX was invented by Dr. Feral Temelli from the
Department of Agricultural, Food & Nutritional Science of the
University of Alberta (U of A) along with Dr. Bernhard Seifried,
now Senior Director of Engineering Research and Technology at
Ceapro. The license from U of A provides Ceapro with exclusive
worldwide rights in all industrial applications.
About Ceapro Inc.Ceapro Inc. is
a Canadian biotechnology company involved in the development of
proprietary extraction technology and the application of this
technology to the production of extracts and “active ingredients”
from oats and other renewable resources. Ceapro adds further value
to its extracts by supporting their use in cosmeceutical,
nutraceutical, and therapeutics products for humans and animals.
The Company has a broad range of expertise in natural product
chemistry, microbiology, biochemistry, immunology and process
engineering. These skills merge in the fields of active
ingredients, biopharmaceuticals and drug-delivery solutions. For
more information on Ceapro, please visit the Company’s website at
www.ceapro.com.
For more information contact:
Jenene ThomasJTC Team, LLCInvestor Relations and Corporate
Communications AdvisorT (US): +1 (833) 475-8247E: czo@jtcir.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
Ceapro (TSXV:CZO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ceapro (TSXV:CZO)
Historical Stock Chart
From Apr 2023 to Apr 2024